Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Approves Device to Treat Brain Cancer

April 18, 2011 6:53 am | by Matthew Perrone | News | Comments

Device maker Novocure said that the Food and Drug Administration approved its first-of-a-kind treatment that fights cancerous brain tumors using electrical energy fields.


Synthes Confirms J & J Deal Being Discussed

April 18, 2011 6:45 am | by John Heilprin | News | Comments

U.S.-Swiss medical device maker Synthes Inc. confirmed it is in talks to be bought out by health giant Johnson & Johnson, in a deal that could make its chairman Switzerland's richest man.


Lilly's 1Q Profit Falls 15%

April 18, 2011 6:42 am | by Tom Murphy | News | Comments

Eli Lilly and Co.'s first-quarter profit fell 15 percent because of severance costs and a diabetes drug development agreement designed to help the drugmaker handle a wave of patent expirations for key products.


Clinical Pharmacology Facility Opens

April 18, 2011 5:55 am | News | Comments

Vince & Associates Clinical Research, Overland Park, Kan., has opened a 90-bed Clinical Pharmacology Research Unit.


Motorized Stage

April 15, 2011 8:29 am | Product Releases | Comments

The Z Axis Motorized Stage from Prior Scientific offers a wide range of positioning solutions for a variety of applications. Many configurable options are available from a simple motorized linear axis to a full three axis stage system.


Low Volume Fraction Collector

April 15, 2011 8:24 am | Product Releases | Comments

Zinsser Analytic has developed µFRACS – an automated low volume fraction collector for µHPLC. µFRACS is a rapid and accurate system that quickly collects small fractions of only a few µLs directly into 384-well or 96-well microtiter plates.


Former Merck CEO Compensation Up 65%

April 15, 2011 8:07 am | by Tom Murphy | News | Comments

Recently retired Merck & Co. CEO Richard Clark saw a 65 percent increase in total compensation last year compared with 2009, when stock price fluctuations reduced stock and option awards given to the drugmaker's top executives.


Tofacitinib Meets Primary Endpoints of ORAL Scan

April 15, 2011 8:04 am | News | Comments

Pfizer Inc. announced top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.


Genes That Control Aging Steroid Identified

April 15, 2011 8:00 am | News | Comments

Eight genes which control levels of the main steroid produced by the adrenal gland, believed to play a role in ageing and longevity, have been uncovered by an international consortium of scientists.


DNA Replication Enzyme Might Be Cancer Drug Target

April 15, 2011 7:58 am | News | Comments

An enzyme essential for DNA replication and repair in humans works in a way that might be exploited as anti-cancer therapy, say researchers at The Scripps Research Institute and Lawrence Berkeley National Laboratory.


Amylin Announces Metreleptin Study Results

April 15, 2011 7:50 am | News | Comments

Amylin Pharmaceuticals, Inc. announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy.


CHMP Recommends Bydureon Approval

April 15, 2011 7:46 am | News | Comments

Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said a European committee has endorsed its potential diabetes treatment Bydureon, a key step toward possible approval in the European Union.


Billion Dollar Drug Dispute Finally Settled

April 15, 2011 7:42 am | News | Comments

Drugmakers Merck and Johnson & Johnson said they've reached a deal to end a multibillion dollar arbitration dispute over rights to two lucrative drugs for immune disorders.


J & J Issues Another Recall

April 15, 2011 7:40 am | by Linda A. Johnson | News | Comments

Johnson & Johnson issued yet another recall , this one for about 57,000 bottles of a widely used epilepsy pill, due to complaints of a chemical odor. The health care giant said it is recalling two lots of 100-milligram tablets of Topamax.


Genome-Wide Array

April 14, 2011 8:09 am | Product Releases | Comments

Affymetrix, Inc. launched the Axiom Genome-Wide CHB 1 Array, the first commercial product to maximize genetic coverage of common alleles in Han Chinese populations. This array is the third population-designed array for the Axiom Genotyping Solution.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.